U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Locally Advanced Endometrial Carcinoma

MedGen UID:
1774338
•Concept ID:
C5418567
•
Neoplastic Process

Definition

Endometrial carcinoma that has spread to nearby tissues or lymph nodes. [from NCI]

Professional guidelines

PubMed

Adjuvant treatment for stage IIIC endometrial cancer: options and controversies.
Shah PH, Kudrimoti M, Feddock J, Randall M
Gynecol Oncol 2011 Sep;122(3):675-83. Epub 2011 Jun 12 doi: 10.1016/j.ygyno.2011.05.018. PMID: 21664661

Recent clinical studies

Etiology

Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.
Matulonis UA, Huang HQ, Filiaci VL, Randall M, DiSilvestro PA, Moxley KM, Fowler JM, Powell MA, Spirtos NM, Tewari KS, Richards WE, Nakayama JM, Mutch DG, Miller DS, Matei D, Wenzel LB
Gynecol Oncol 2022 Feb;164(2):428-436. Epub 2021 Dec 11 doi: 10.1016/j.ygyno.2021.11.021. PMID: 34903380Free PMC Article
Adjuvant treatment for stage IIIC endometrial cancer: options and controversies.
Shah PH, Kudrimoti M, Feddock J, Randall M
Gynecol Oncol 2011 Sep;122(3):675-83. Epub 2011 Jun 12 doi: 10.1016/j.ygyno.2011.05.018. PMID: 21664661
Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients.
Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Romanini C
Gynecol Oncol 1996 Apr;61(1):16-21. doi: 10.1006/gyno.1996.0089. PMID: 8626110
The relationship of clinical-pathologic status and adjuvant treatment with natural killer cell activity in stage I and II endometrial carcinoma.
Garzetti GG, Ciavattini A, Muzzioli M, Goteri G, Fabris N, Valensise H, Romanini C
Acta Obstet Gynecol Scand 1994 Sep;73(8):652-7. doi: 10.3109/00016349409013461. PMID: 7941992

Diagnosis

Adenocarcinoma of the urinary bladder presenting as locally advanced endometrial carcinoma. Case report and review of the literature.
Chura JC, Brooker D, Downs LS Jr
Gynecol Oncol 2006 Oct;103(1):336-41. Epub 2006 Jun 21 doi: 10.1016/j.ygyno.2006.04.018. PMID: 16793125
Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients.
Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Romanini C
Gynecol Oncol 1996 Apr;61(1):16-21. doi: 10.1006/gyno.1996.0089. PMID: 8626110
The relationship of clinical-pathologic status and adjuvant treatment with natural killer cell activity in stage I and II endometrial carcinoma.
Garzetti GG, Ciavattini A, Muzzioli M, Goteri G, Fabris N, Valensise H, Romanini C
Acta Obstet Gynecol Scand 1994 Sep;73(8):652-7. doi: 10.3109/00016349409013461. PMID: 7941992

Therapy

Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.
Matulonis UA, Huang HQ, Filiaci VL, Randall M, DiSilvestro PA, Moxley KM, Fowler JM, Powell MA, Spirtos NM, Tewari KS, Richards WE, Nakayama JM, Mutch DG, Miller DS, Matei D, Wenzel LB
Gynecol Oncol 2022 Feb;164(2):428-436. Epub 2021 Dec 11 doi: 10.1016/j.ygyno.2021.11.021. PMID: 34903380Free PMC Article
Adjuvant treatment for stage IIIC endometrial cancer: options and controversies.
Shah PH, Kudrimoti M, Feddock J, Randall M
Gynecol Oncol 2011 Sep;122(3):675-83. Epub 2011 Jun 12 doi: 10.1016/j.ygyno.2011.05.018. PMID: 21664661
Adenocarcinoma of the urinary bladder presenting as locally advanced endometrial carcinoma. Case report and review of the literature.
Chura JC, Brooker D, Downs LS Jr
Gynecol Oncol 2006 Oct;103(1):336-41. Epub 2006 Jun 21 doi: 10.1016/j.ygyno.2006.04.018. PMID: 16793125
The relationship of clinical-pathologic status and adjuvant treatment with natural killer cell activity in stage I and II endometrial carcinoma.
Garzetti GG, Ciavattini A, Muzzioli M, Goteri G, Fabris N, Valensise H, Romanini C
Acta Obstet Gynecol Scand 1994 Sep;73(8):652-7. doi: 10.3109/00016349409013461. PMID: 7941992

Prognosis

Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients.
Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Romanini C
Gynecol Oncol 1996 Apr;61(1):16-21. doi: 10.1006/gyno.1996.0089. PMID: 8626110

Clinical prediction guides

Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.
Matulonis UA, Huang HQ, Filiaci VL, Randall M, DiSilvestro PA, Moxley KM, Fowler JM, Powell MA, Spirtos NM, Tewari KS, Richards WE, Nakayama JM, Mutch DG, Miller DS, Matei D, Wenzel LB
Gynecol Oncol 2022 Feb;164(2):428-436. Epub 2021 Dec 11 doi: 10.1016/j.ygyno.2021.11.021. PMID: 34903380Free PMC Article
Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients.
Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Romanini C
Gynecol Oncol 1996 Apr;61(1):16-21. doi: 10.1006/gyno.1996.0089. PMID: 8626110

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...